U.S. buys more Relenza and Tamiflu for future influenza pandemics

The United States Department of Health and Human Services has announced additional purchases of antiviral drugs that could be used in the event of a potential influenza pandemic.

The department has ordered 2.2 million more treatment courses of antiviral drug zanamivir (Relenza) from GlaxoSmithKline and 3.8 million more treatment courses of oseltamivir phosphate (Tamiflu) from Roche. With these purchases, the Strategic National Stockpile will have a total of 26 million treatment courses of antiviral drugs for distribution to the states when an influenza pandemic is deemed to be imminent.

"Our ultimate goal is to stockpile sufficient quantities of antiviral drugs to treat 25% of the U.S. population," Secretary Leavitt said. "We also hope these purchases will stimulate development of expanded domestic production capacity in order to accommodate subsequent needs through normal commercial transactions."

President Bush has outlined a coordinated government strategy that includes establishing the new International Partnership on Avian and Pandemic Influenza, stockpiling antiviral medications, enhancing domestic capacity to develop and manufacture influenza vaccines and dose-sparing technology, expanding early-warning systems domestically and abroad and new funding and initiatives for local and state level preparedness.

As part of the Administration's goal to enhance state and local pandemic preparedness, HHS senior officials now have participated at summits in 26 states and the District of Columbia. To date, pandemic preparedness planning summits have been held in Alabama, Arizona, Connecticut, Delaware, District of Columbia, Florida, Georgia, Kentucky, Illinois, Iowa, Maryland, Massachusetts, Minnesota, Missouri, Nebraska, Nevada, North Carolina, North Dakota, Ohio, Pennsylvania, Rhode Island, South Carolina, South Dakota, Vermont, West Virginia, Wisconsin and Wyoming.